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Abstract
Pfsl6 is a sexual stage/sporozoite-specific antigen of Plasmodium falciparum and is a potential candidate for a 
sporozoite-neutralizing vaccine. To obtain more information on the function of Pfsl6  and to investigate its role during 
transmission and hepatocyte invasion, immunization experiments were performed with both a Pfs 16-specific recombinant 
vaccinia virus and virus-like particles produced in yeast composed of the hepatitis B surface antigen (HBsAg) and antigen 
Pfs 16 fused to HBsAg. Upon transformation of yeast cells, harbouring a genomic copy of the HBsAg gene, with a plasmid 
carrying the fusion gene Pfsl6 -HBsAg (Pfsl6 -S) virus-like hybrid particles composed of HBsAg and Pfsló-S were formed 
of a size similar to those present in human sera after infection with the hepatitis B virus. Cells infected with recombinant 
Pfsl6 vaccinia virus synthesized a polypeptide of approx. 16 kDa that reacted with a Pfs 16-specific polyclonal antibody. 
Animals vaccinated with the yeast hybrid particles and/or recombinant vaccinia virus both produced Pfsl6 -specific
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antibodies. These antibodies showed no transmission-blocking activity, but they efficiently diminished or abolished in vitro 
invasion of sporozoites into human hepatoma cells (HepG2-A16) and primary human hepatocytes.
Keywords: Plasmodium falciparum; P fsl6 ; Recombinant vaccinia virus; Heterologous production; Yeast; Sporozoite-neutralizing vaccine
1. Introduction
Sporozoites are the infective stage of the malaria 
parasite and are found in the salivary glands of 
female Anopheles mosquitoes. During feeding, 
mosquitoes inject sporozoites into the host’s circula­
tion which rapidly invade hepatocytes and develop 
into thousands of merozoites. After rupture of hepa- 
tocytes, these merozoites initiate repeated cycles of 
erythrocyte infection associated with clinical disease. 
Irradiated sporozoites elicit protective immunity in 
rodents, monkeys and humans and led to the identifi­
cation of the circumsporozoite (CS) protein and the 
sporozoite surface 2 protein (SSP2) [1-5]. There is 
now compelling evidence indicating that the immu­
nity induced by irradiated sporozoites is mediated by 
anti-sporozoite antibodies, as well as CD4 4- and 
CD8  +  cells that recognize sporozoite-infected hepa­
tocytes [6 ]. CS protein has been the focus of most 
efforts to develop a pre-erythrocytic stage malaria 
vaccine. However, despite many efforts, thus far 
only a few volunteers have been protected with 
recombinant or synthetic CS vaccines [7,8].
Recently, we reported the presence of the highly 
conserved 16-kDa protein P fs l6  on the surface of 
both sexual-stage parasites and sporozoites [9,10]. 
Rabbit sera raised against a synthetic peptide and 
against recombinant fusion proteins produced in Es­
cherichia coli recognize a 16-kDa antigen in protein 
extracts of gametocytes, macrogametes and sporo­
zoites by Western blot analysis [9]. By one- and 
two-dimensional Western blot analysis using P fsl6 
specific monoclonal antibodies it was demonstrated 
that these 16-kDa proteins produced by gametocytes 
and sporozoites are identical (unpublished data). By 
immunoelectron microscopy, P fs l6 was localized on 
the surface of sporozoites and in the parasitophorous 
vacuole membrane of gametocytes [9,11,12].
We further investigated whether P fs l6  is a candi­
date malaria vaccine antigen that might elicit protec­
tive antibodies that could neutralize sporozoite infec- 
tivity or block transmission. To begin development 
of suitable P fsl6  vaccines, we report in this study the 
expression of P fsl6  or P fsl6  fragments, in yeast and 
mammalian cells. Yeast provides a simple and inex­
pensive means for recombinant protein production
[13]. Very recently, the RTS,S vaccine produced in 
yeast, containing the hepatitis B virus envelope pro­
tein as a carrier for B-cell and T-cell epitopes of the 
central repeat region and the C-terminal region of the 
CS protein, has proven to be safe and immunogenic 
during a clinical study conducted in Thailand [14]. 
Live attenuated viruses, such as vaccinia virus are 
attractive vectors for vaccine development because 
they are easily administered, inexpensive to produce 
and stress-resistant during transport. Vaccinia virus 
has been used for the production of a large number 
of antigens from pathogenic organisms, and in sev­
eral cases vaccination with these recombinant viruses 
conferred immunity to a subsequent challenge 
[15,16]. Viral vectors stimulate different arms of the 
immune system, which is valuable for vaccine devel­
opment [17,18].
Antisera were prepared with both recombinant 
vaccinia virus and a recombinant Pfsl6  fusion pro­
tein prepared from yeast. These sera were tested for 
their capacity to inhibit in vitro sporozoite invasion 
into human hepatoma cells and hepatocytes, and 
transmission-blocking activity.
2. Materials and methods
2.L Construction o f recombinant plasmids
2.1.1. Tcd5 /  16-S
Recombinant plasmids were constructed and iso­
lated by standard methods using E. coli MM294 
(F", endAl, thi, hsdR17, supE44, lambda- ) as 
“ host” [19]. For the production of Pfs 16-specific
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fusion proteins in yeast the shuttle vector Tcd5 was 
used. It contains an expression cassette consisting of 
the yeast glyceraldehyde-3-phosphate dehydrogenase 
(TDH3) promoter fused to the gene coding for 
HBsAg followed by a yeast transcription termination 
region of the ARG3 gene. The Leu2 gene serves as a 
selection marker. Both at the 5' and 3' ends of the 
expression cassette TY1 sequences were inserted
[2 0 ] to achieve homologous recombination between 
the expression cassette and TY1 sequences present 
within the yeast genome. To create fusions between 
the Pfsl6  gene and the gene coding for the hepatitis 
B  surface antigen (HBsAg) a PCR fragment coding 
for amino acids 20-104 of P fsl6  was cloned into the 
unique Smal site of the shuttle vector Tcd5 (Fig. 
1A). The plasmid containing the P fsl6  sequence was 
designated Tcd5/16-S. The resulting chimeric gene
encodes a protein (P fsl6 -S) of which the deduced 
amino-acid sequence is shown in Fig. IB.
The Tcd5/16-S plasmid was digested with X hol 
and the resulting fragments were separated by 
agarose-gel electrophoresis according to standard 
procedures [19]. The fragment T cd 5/16-S “A7toI, 
containing the TY1, Leu2 and the expression cassette 
sequences, was then isolated by electroelution [19]. 
Subsequently, Saccharomyces cerevisiae strain 
Y1295 (MATa, leu2-3, leu2-112), already contain-
4 -5  copies of the HBsAg gene in its genome, 
was transformed with the Tcd5/16-S-.A7iöI fragment 
via the spheroplast transformation method described 
by Hinnen and co-workers [21]. Stable transformants 
were selected by selection for leucine auxotrophy. 
The transformant containing both a copy of the 
P fsl6 -S fusion gene and 4 -5  copies of the HBsAg
(Si
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241 IP1P83WAFAKYLWEWAfiVFl FSWLQLLVPFVQWFVÛLâPT
261 VWLSAIWWHWYWGP8LY31VQPFIPLLPIFFCLWVYI
EcoRI
Fig. 1. (A) Schematic representation of plasmid Tcd5/16-S, (B) Amino-acid sequence of the fusion protein Pfsl6 -S. It consists of the P fsl6 
antigen ( = = )  devoid of the signal peptide sequence (amino acids 1-19) and the putative membrane anchor and cytoplasmic region 
(amino acids 105-157) fused to the hepatitis B surface antigen ( --------- ).
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gene was called Y1655 and the hybrid particles 
composed of HBsAg and P fs l6 -S (P fsl6 -HBsAg 
fusions) were designated P fsl6 -S,S.
2.1.2. Construction o f  recombinant vaccinia virus 
transfer vector p S C ll  / 1 6
Transfer vector p S C ll contains a compound 
early/late promoter of moderate strength, P75, fol­
lowed by a unique Sm a\ site and flanked by frag­
ments (TK1 and TKr) of the vaccinia thymidine 
kinase (TK) gene [22], It also contains the late 
vaccinia virus promoter Pn , that is used for the 
expression of the E. coli lacZ reporter gene. The 
recombinant P fs l6  specific transfer vector p S C ll /1 6  
was constructed via insertion of a PCR fragment, 
encompassing the complete coding information of 
P fs l6 , into the unique Smal site. Recombinants were 
constructed and propagated by standard methods [19].
For the construction of recombinant viruses ac­
cording to standard methods vaccinia virus strain 
WR, a gift of Dr. L. Boryciewicz (University of 
Cambridge, Cambridge, UK), was used. It was prop­
agated and purified as reported previously [23]. CV-1 
cells infected with wild-type vaccinia virus were 
transfected with calcium phosphate-precipitated plas­
mid (p S C ll /1 6 )  DNA [22]. For identification and 
purification of recombinant viruses TK selection and 
/3-galactosidase screening was used [22], TK-recom- 
binants producing /3-galactosidase were selected by 
plaque assay on RAT- 2  cells (TK- ) in the presence 
of 5-bromo-deoxyuridine (BUdR) and X-Gal (60 fig  
m l-1 ). Plaques were visualized after approx. 6  h of 
incubation at 37°C. After two to three selection 
procedures, recombinant virus (v S C ll/1 6 )  was am­
plified in RAT-2 cells [23]. CV-1 and RAT-2 cells 
were grown in Dulbecco’s Modified Eagle's Medium 
(DMEM, GIB CO Laboratories) containing 10% fetal 
bovine serum (FBS) and for the TK“ cells 25 /xg of
5-bromo-deoxyuridine (BUdR) per ml was added to 
the medium.
2.2. Analysis o f the synthesis o f  recombinant proteins 
in yeast
Synthesis of the recombinant proteins P fsl6 -S and 
HBsAg was monitored by immunoblot analysis of 
total extracts using rabbit polyclonal antiserum 
K37S8 (anti-Pfsl6 ) [9] and mouse monoclonal anti­
body, HBS1 (anti-HBsAg), respectively. Preparation 
of crude cell extracts and immunoblot analysis was 
performed as described [24].
2.3. Characterization of yeast particles containing 
recombinant Pfs 16-specific fusion protein
HBsAg synthesized in yeast is accumulated in 
particles similar in size as the 2 2 -nm particles found 
in human sera after hepatitis B infection which have 
a buoyant density of 1.18 g cm “ 3 [25]. To study 
whether the recombinant P fsl6 -S fusion proteins and 
HBsAg synthesized in yeast Y1655 also accumulate 
in 22 nm particles, crude extracts of Y1655 yeast 
cells were subjected to CsCl equilibration centrifuga­
tion as described [24]. In short, crude cell extract, 
equivalent to approx. 15 mg of cell protein, was 
mixed with 1,5 M CsCl in sodium phosphate buffer 
(pH 7,4) and centrifugated in a 50 Ti (Beckman) 
rotor at 45 000 rpm for 72 h at 8 °C. After centrifuga­
tion 0.5-ml fractions were collected by puncturing 
the bottom of the tube. Subsequently, 2 p \  of each 
fraction was analyzed for the presence of HBsAg via 
the radioimmunoassay AUSRIA II (Abbott Labora­
tories) and 1 0  fi\ was used for immunoblot analysis 
to study the presence of the P fsl6 -S fusion protein 
and HBsAg antigen, utilising antisera K37S8 and 
HBS1, respectively.
2.4. Expression o f gene P fsló  using recombinant 
vaccinia virus vSCU  / 1 6
To study the expression of gene Pfsló after infec­
tion with recombinant vaccinia virus v S C ll/1 6 , a 
confluent RAT-2 cell monolayer was used. 48 h after 
infection cells were harvested by low-speed centrifu­
gation and the pellet fraction was resuspended in 400 
jjl\ of SDS/sam ple buffer and heated for 5 min at 
95°C. To establish whether a P fsl6  protein of appro­
priate size was made immunoblot analysis was per­
formed using K37S8 as antiserum.
2.5. Isolation o f gametocytes and sporozoites
Isolation of sporozoites was performed using the 
urografin gradient method as described by van Pelt 
and co-workers [26], Gametocytes were isolated as 
described [9,27].
LÎ.M.D. Moelans et a l /Molecular and Biochemical Parasitology 72 (1995) 179-192 183
2.6. Western blot analysis
For Western blot analysis of sporozoite (SWB) 
and gametocyte (GWB) antigens, samples containing 
approx. 3 X 106 parasites were boiled for 5 min in 
25 fi\ of sample buffer (62.5 mM Tris • H C l/2 % 
SDS/10%  glycerol/5% 2-mercaptoethanol/0.003% 
Bromophenol blue, pH 7.2). Subsequently, the sam­
ples were loaded onto a SDS-12.5% polyacrylamide 
gel and electrophoresis was carried out according to 
standard methods [19,28]. The samples were then 
transferred to nitrocellulose by electroblotting as de­
scribed [29]. The blot was then washed for 5 min in 
PBST (phosphate-buffered saline (PBS) supple­
mented with 0.1% Tween-20) followed by blocking 
of the unspecific binding sites by incubation for 1 h 
in PBST buffer supplemented with 3% BSA. Visual­
ization of the respective antigens was performed as 
described [9].
2.7. Indirect immunofluorescence assay (IFA)
Sporozoites from salivary glands were counted 
and diluted to 1000 sporozoites per 10 fi\ of PBS. 
Drops of 20 fjbl were pipetted in each of the 1 2  wells 
of multitest slides, air dried and stored at — 70°C. 
Sera were diluted in PBS and 20 p  1 of the appropri­
ate dilutions were applied to the wells containing 
sporozoites. After 20 min incubation in a moist 
chamber at 37°C, the slides were washed thrice with 
PBS. Fluorescein-conjugated goat anti-rabbit or rab­
bit anti-mouse IgG antiserum was then added at a 
dilution of 1:50 (in 0.05% Evans Blue) and the slides 
were incubated for another 20 min. After an addi­
tional wash in PBS, 50% glycerol in PBS was added 
to the samples and they were analyzed by fluores­
cence microscopy.
2.8. Suspension indirect immunofluorescence assay
(SIFA)
For SIFA, 100000 sporozoites purified by the 
urografin gradient method were suspended in 10  jjl\ 
of PBS and incubated at room temperature for 20 
min with the appropriate antiserum. Following low- 
speed centrifugation the sporozoites were washed
twice with 100 fjbl of PBS prior to incubation for 20 
min at room temperature with 1 0  pA of goat anti-rab- 
bit or rabbit anti-mouse FITC-conjugated antiserum 
at a dilution of 1:50 (in 0.05% Evans Blue). After 
several washings with PBS, samples of 10 ¿¿1 
(100000 sporozoites) in PBS were applied to slides 
and covered by coverslips and they were analyzed by 
fluorescence microscopy.
2.9. Enzyme-linked immunosorbent assay (ELISA)
Microtiter plates were coated with 1 jjLg per well 
of GST/B-D, a P fsl6 -encoded polypeptide fused to 
the C terminus of Schistosoma japonicum glu­
tathione S-transferase, produced in E. coli [9]. A s­
says were performed as described [9]. Titers of 1:100 
or less were considered negative.
2.10. Sporozoite invasion in vitro
Tests of inhibition of sporozoite invasion (ISI) 
were carried out both with human hepatoma 
(HepG2-A16) cells and with primary cultures of 
human hepatocytes, propagated on glass coverslips 
(diameter 15 mm). Primary cultures of human hepa­
tocytes were obtained as described previously [30]. 
HepG2-A16 cells were grown at 37°C in 5% C 0 2 in 
air to a confluent monolayer in DMEM supple­
mented with 2 mM glutam ine/10% fetal calf 
serum /100 U each of penicillin and streptomycin 
per ml medium. The culture medium was then re­
placed by DMEM without supplements and (anti)sera 
were diluted in the appropriate medium and added to 
the cell cultures. To the HepG2-A16 cells (350000) 
and primary human hepatocytes (175000) 30000  
and 150000 sporozoites, respectively, were then 
added per coverslip and incubation was continued 
for 3 h at 37°C in 5% C 0 2. Subsequently, the 
coverslips were washed several times with PBS. The 
cell monolayers were then fixed with methanol ( 1 0  
min), followed by three washes with PBS. Penetrated 
intracellular sporozoites surrounded by a membrane 
were revealed by an immunoperoxidase antibody 
assay using a monoclonal antibody to P. falciparum 
CS (3sp2) as described [26,31]. All experiments were 
carried out at least in duplicate.
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Fig. 2. Immunoblot analysis of recombinant proteins synthesized 
in Y1295 yeast cells transformed with expression cassette 
Tcd5/16-S-^7f£>I. Proteins that react with HBsAg-specific mono­
clonal antibody HBS1 are shown in lanes 1 and 2. Proteins that 
react with P fsl6 -specific antiserum K37S8 are shown in lanes 3 
and 4. Per lane 50 /¿g of total cellular protein was applied.
2.11. Transmission-blocking assay (TB assay)
Mice and rabbit sera were tested for transmission 
blocking activity in a bioassay by membrane feeding 
of cultivated gametocytes of NF54 to female 
mosquitoes in the presence of test or control sera 
[32],
2.12. Immunoelectron microscopy
Immunoelectron microscopy was used to localize 
the Pfsl6  antigen in the exo-erythrocytic stages of P. 
falciparum . Immunoelectron microscopy was per­
formed as described [33],
2.13. Animals and immunization
Two B alb /c mice (M3 and M4) and New Zealand 
rabbits (R38 and R39) were immunized with purified 
recombinant yeast particles (P fsl6 -S,S) composed of 
the recombinant proteins P fs l6 -S and HBsAg. Alum 
was used as adjuvant. Rabbits were immunized via 
subcutaneous injection in weeks 0, 3 and 6  with 50 
fig  of recombinant protein. Mice were immunized in 
weeks 0, 3 and 7 with 20 fig  of yeast particles. 
Serum was obtained from the animals two weeks 
after the third immunization (R38S3, R39S3, M3S3, 
M4S3). Rabbits R57 and R64 were inoculated intra- 
veneously in weeks 0 and 7 with (1-2.5) X 107 
plaque forming units of the recombinant P fsl6  vac­
cinia virus v S C ll /1 6  and serum was obtained 2 
weeks after the second inoculation (R57S2, R64S2). 
Several weeks after the third P fsl6 -S,S boost rabbit
A
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Fig. 3. CsCl gradient centrifugation of crude cell extracts prepared from yeast Y1655 cells producing recombinant Pfsl6-S and HBsAg 
proteins. Tube fractions are numbered from bottom to top. Fractions were analyzed for their HBsAg activity by the radioimmunoassay 
AUSRIA II (A), and were analyzed by immunoblot analysis using K37S8 (B) and HBS1 (C) to demonstrate the production of recombinant 
P fsl6 -S and HBsAg proteins.
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R39 was also infected subcutaneously with 107 
plaque forming units of the recombinant vaccinia 
virus and serum was collected 2 2  days after inocula­
tion (R39v22). As controls, mouse (M2S2) and rab­
bit (R8S2) antisera raised against recombinant fusion 
proteins consisting of CS-epitopes and HBsAg pro­
duced in yeast [13] were used. Pre-sera from mice 
M2, M3 and M4 (M1S0) and rabbits R8 , R38, R39, 
R57, R64 (R8S0, R38S0, R39S0, R57S0, R64S0) 
were taken as controls from all mice and rabbits just 
before the first immunizations. All antisera were
used in ELISA, Western blot analysis, IFA, SIFA, 
TB assay and ISI.
3. Results
3.1. Identification o f recombinant proteins synthe­
sized in yeast
To study the expression of P fs l6 -S and HBsAg in 
yeast Y1655 cells cellular proteins were analyzed by
Table 1
Summary of reactivities of various mouse (M1S0, M2S2, M3S3 and M4S3) and rabbit antisera (R8S0, R8S2, R38S0, R38S3, R39S0, 
R39S3, R39v22, R57S0, R57S2, R64S0 and R64S2) in ELISA, IFA, SIFA and immunoblotting with P. falciparum  gametocyte and 
sporozoite proteins
Scrum ELISA IFA SIFA SWB 
Pfsl6 a CS a
GWB
M1SQ
(pre-serum)
< 1 : 1 0 0 — — ND ND
M2S2 
(CS 4- HBsAg)
< 1 :1 0 0 4- 4- -1- 4* -f- + ND ND
M3S3
(Pfsl6-S,S)
1:16000 + 4- 4- ND ND
M4S3
(Pfsl6 -S,S)
1:4000 + + ND ND
R8S0
(pre-serum)
< 1 :1 0 0 " r r ’ J 1““-A 1
R8S2 
(CS + HBsAg)
< 1 : 1 0 0 + 4- + 4- 4- 4. -1—1_
R38S0
(pre-serum)
< 1 : 1 0 0 L " L
R38S3
(Pfsl6-S,S)
1 :2 0 0 0 4- +
"
+  4-
R39S0
(pre-serum)
< 1 :1 0 0 m
R39S3
(Pfsl6 -S,S)
1 :1 0 0 0 4- 4- ~'s 4_
R39v22
(Pfsl6-S,S
+ VSC11/16)
1 : 1 X 106 + + + 4—h 4~ + 4- 4- 4-
R57S0
(pre-serum)
< 1 :1 0 0 ■ IlhN
R57S2
(vSCll/16)
1:19200 4~ +  / - 4- 4- +  +  +
R64S0
(pre-serum)
< 1 : 1 0 0
R64S2
(vSCll/16)
1:76 800 4- 4- 4- + H—1-4-
The symbols —, 4- /  — , + , 4- 4- and 4- + 4 - reflect an increasing intensity of reactions. SWB, sporozoite Western blot analysis; GWB, 
gametocyte Western blot analysis; ND, not determined. 
a Reactivity with Pfsl6 or CS protein.
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immunoblot analysis using both a monoclonal anti­
body HBS1, specific for the HBsAg monomer, and a 
polyclonal antiserum K37S8, raised against the re­
combinant P fsló  fusion protein produced in E, coli
[9]. As shown in Fig. 2 the monoclonal antibody 
HBS1 reacted with two proteins with molecular 
masses of 22 and 32 kDa, respectively, while the 
Pfs 16-specific polyvalent antiserum reacted only with 
the 32-kDa protein. From these results it can be 
concluded that in Tcd5 /16-S-X hoI transformed yeast 
Y1295 cells the recombinant proteins P fsl6 ~S and 
HBsAg are produced.
Studies on the expression of hepatitis B surface 
antigen coding sequences in yeast have demonstrated 
that these proteins spontaneously aggregate in virus­
like particles with a diameter of 2 2  nm which readily 
can be separated from other proteins by CsCl density 
gradient centrifugation [25] exhibiting a density of
fS
1.2 g cm~~. These characteristics are also observed 
for the particles found in human patients after a 
hepatitis B virus infection. To study whether also the 
proteins P fs l6 -S and HBsAg are assembled in 2 2  nm 
particles crude cell extracts of Y1655 cells were 
subjected to CsCl equilibration centrifugation [24]. 
After centrifugation fractions were collected by 
puncturing the bottom of the tube. Subsequently, part 
of each fraction was analyzed by the radioim­
munoassay AUSRIA II for HBsAg antigenic activity 
and another part was analyzed by Western blot ana- 
lysis for the presence o f P fs l6  specific antigens (Fig. 
3). In addition, the density of each fraction was 
determined. Since for recognition in the AUSRIA II 
assay the HBsAg antigen must have a native confor­
mation, the data of Fig. 3A show that fractions
15-20 contain most of the native HBsAg. The aver­
age buoyant density of the particles present in these 
fractions was found to be 1.202. To estimate the 
efficiency of assembly of both HBsAg and P fsl6 -S 
into 2 2  nm particles, immunoblot analysis of the 
gradient fractions was also performed with sera HBS1 
and K37S8 that recognize linear epitope(s) on the 
HBsAg and P fsl6  monomers, respectively. Fig. 3B 
and 3 C show that most of the HBsAg and P fsl6 -S 
proteins are found in fractions 15-20, demonstrating 
that the results of the immunoblot analysis follow the 
data of the AUSRIA II radioimmunoassay (Fig. 3A). 
From the results obtained from the immunological 
analysis and from the measurements of the refraction 
indices it can be concluded that the proteins P fsl6 -S 
and HBsAg assemble into 22-nm particles (Pfsl6 - 
S,S) and as efficient as native HBsAg [25].
3.2. Immunogenicity o f Pfsl6-S,S particles
To evaluate the immunogenicity of purified 
Pfsl6 -S,S particles, mice and rabbits were immu­
nized as indicated in Materials and methods. Subse­
quently, serum samples were analyzed for the pres­
ence of Pfs 16-specific antibodies by an ELISA. Titers 
up to 1:16000 were obtained (Table 1). Western blot 
analysis showed that sera R38S3 and R39S3 specifi­
cally reacted with a 16-kDa protein present in total 
protein extracts of both gametocytes and sporozoites. 
Serum R8S2, which was raised against yeast parti­
cles containing HBsAg and CS epitopes, only re­
acted with the CS protein in a sporozoite Western 
blot. As indicated in Table 1, indirect immunofluo­
rescence assays revealed that all P fsl6 -specific anti-
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Fig. 4. Western blot analysis of protein extracts prepared from sporozoites (lane 1) and gametocytes (lane 2) using rabbit antiserum R57S2 
(B), negative control serum R57S0 (A), antiserum R39v22 (D) and control pre-serum R39S0 (C). Antiserum R57S2 was collected two 
weeks after the second inoculation with recombinant vaccinia virus vSC ll/16 . Antiserum R39v22 was recovered at day 22  after infection 
with recombinant vaccinia virus v S C ll/1 6  of rabbit R39 which was already immunized thrice with yeast hybrid particles Pfsl6-S,S.
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sera reacted with sporozoites in an IFA and fluores­
cence on the surface was observed when the SIFA 
was performed with unfixed live sporozoites, al­
though the intensities were less than obtained after 
staining with the CS-specific antisera M2S2 and 
R8S2. As a control, pre-immune sera were used. 
They did not give any reaction on the Western blots 
and there was no fluorescense in IFA or SIFA (Table 
1), From these results it can be concluded that as a 
result of vaccination with the P fsl6 -S,S particles
Pfsló-specific antibodies are induced. Moreover, the 
present study confirms and extends earlier observa­
tions that the P fsl6 antigen is present on the surface 
of sporozoites.
3.3. Production o f P fsl6 in recombinant vaccinia 
virus-infected cells
Expression of the heterologous gene in cells in­
fected with recombinant vaccinia virus v S C l l /1 6
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Fig. 5. Localization of the Pfsl6 antigen by immunoclectron microscopy utilising antiserum R57S2. (A) Sporozoites in mosquito salivary 
gland, demonstrating the gold label abundantly present at the surface. (B) Sporozoite in close contact with a human hepatoma cell. (C) 
Livcr-stage parasite in HepG2-A16 cell after infection by sporozoites. Gold label is primarily associated with the outer surface of the 
exoerythrocytic schizont. Bars =  0.4 /Am.
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Table 2
Effect of various mouse (M1S0, M2S2, M3S3, M4S3) and rabbit antisera (R8S0, R8S2, R38S0, R38S3, R39S0, R39S3, R39v22, R57S0, 
R57S2, R64S0, R64S2) on sporozoite invasion in HepG2-A16 cells and human hepatocytes
Serum ISI
HepG2-A16 Primary hcpatocytes
dilution #inv.sp. %ISI dilution #inv.sp. %ISI
M1S0 1 100 72 0 1:100 64 0
(pre-serum) 1 2 0 0 119 0
1 1000 151 0
1 2 0 0 0 308 0
1 10000 335 0
M2S2 1 100 7 90 1:100 56 12.5
(CS + HBsAg) 1 2 0 0 4 97
1 1000 17 89
1 2 0 0 0 64 79
1 10000 153 57
M3S3 1 100 ND ND 1:100 36 44
(Pfsl6 -S,S) 1 2 0 0 ND ND
1 1000 70 54
1 2 0 0 0 210 32
1 1 0 0 0 0 262 26
M4S3 1 100 6 92 1 : 1 0 0  21  67
(Pfsl 6 ~S,S) 1 2 0 0 20 83
1 1000 60 60
1 2 0 0 0 330 0
1 1 0 0 0 0 390 0
R8S0 (pre-scrum) 1 100 90 0 ND
R8S2 (CS + HBsAg) 1 100 3 96 ND
R38S0 1 100 168 0 ND
(p re-serum) 1 1000 197 0
1 2 0 0 0 209 0
1 1 0 0 0 0 212 0
R38S3 1 100 55 67 ND
(Pfsl6 -S,S) 1 1 0 0 0 101 49
1 2 0 0 0 129 38
1 1 0 0 0 0 132 38
R39SO 1 100 178 0 ND
(pre-serum) 1 1000 162 0
1 2 0 0 0 160 0
1 10000 159 0
R39S3 1 100 31 83 ND
(Pfsl6 -S,S) 1 1000 88 46
1 2 0 0 0 98 38
1 10000 149 0
R39v22 1 100 7 96 ND
(Pfsl6 -S,S 1 1000 45 75
+ VSC11/16) 1 2 0 0 0 72 61
1 10000 145 22
R57S0 (pre-serum) 1 100 85 0 ND
R57S2 (v S C ll/1 6 )  1 100 33 62 ND
R64S0 (pre-serum) 1 100 34 0 ND
R64S2(vSC 11/16) 1 100 54 0 ND
More information about these sera is given in Materials and methods. ISI is expressed as percentage of invasion reduction as compared to 
the pre-serum. # , number of sporozoites that were able to invade HepG2-A16 cells or primary hepatocytes.
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was analyzed by Western immunoblots. Western 
blots were prepared of cell extracts and incubated 
with Pfsl6 -specific polyclonal antiserum K37S8 [9]. 
In recombinant vaccinia virus infected cells but not 
in uninfected cells or in cells infected with wild type 
virus, a protein with a molecular mass of approx. 16 
kDa could be demonstrated (data not shown).
3.4. Production o f Pfsl6-specific antisera with re­
combinant vaccinia virus
To determine whether the vaccinia virus recombi­
nants were able to induce specific and strong im­
mune responses to the P fsl6  protein, rabbits were 
infected twice with recombinant vaccinia virus 
v S C ll/1 6 . After collection the antisera (R57S2 and 
R64S2) were first analyzed for the presence of 
Pfsl 6 -specific antibodies by ELISA. As shown in 
Table 1, high antibody titers were reached. Subse­
quently, the antisera were analyzed for the presence 
of antibodies reactive to P fsl6  by Western blot 
analysis of whole lysates prepared from gametocytes 
and sporozoites (Fig. 4). As shown in Fig. 4, West­
ern blot analysis demonstrated that the antisera R57S2 
and R64S2 reacted specifically with the 16-kDa pro­
tein as present in sporozoites and gametocytes. Fur­
thermore, IFA and SIFA revealed that the antisera 
also reacted specifically with antigens present on 
fixed and live P. falciparum  sporozoites (Table 1), 
respectively. Moreover, immunoelectron microscopy 
demonstrated the presence of the P fsl6  antigen at the 
surface of sporozoites, as well as at the outer surface 
of exoerythrocytic schizonts collected after invasion 
of HepG2-A16 cells by sporozoites (Fig. 5). No 
reaction was observed with the pre-sera R57S0 and 
R64S0.
The results of an additional infection of rabbit 
R39 with recombinant vaccinia virus v S C ll /1 6  sev­
eral weeks after the third P fsl6 -S,S boost are also 
presented in Table 2. The ELISA results showed that 
a very high Pfs l  6 -specific antibody titer was ob­
tained when compared to the titers seen after immu­
nization with P fsl6 -S,S or v S C ll /1 6  alone. Anti­
serum R39v22 also reacted with the P fsl6  antigen on 
both a gametocyte and a sporozoite Western blot 
(Fig. 4). We could also demonstrate a strong reactiv­
ity of the serum with the surface of sporozoites in 
the IFA and SIFA.
3.5. Transmission-blocking activity
All mice and rabbit sera were tested for transmis­
sion-blocking activity in a standard bioassay as de­
scribed in Materials and methods. None of the anti­
sera showed transmission-blocking activity.
3.6. Inhibition o f sporozoite invasion (ISI) in vitro
We used the inhibition of sporozoite invasion 
(ISI) into cultured cells assay [31,34] to investigate 
whether sera from mice and rabbits vaccinated with 
yeast P fsl6 -S,S particles and/or recombinant vac­
cinia virus were able to neutralize sporozoite infec- 
tivity. Positive controls were antisera raised in mouse 
(M2S2) and rabbit (R8S2) against yeast particles 
containing CS and HBsAg epitopes. Antisera from 
mice (M3S3 and M4S3) and rabbits (R38S3 and 
R39S3) immunized with yeast P fs l6 -S,S particles 
significantly reduced invasion of sporozoites into 
HepG2-A16 cells, although their capacity to reduce 
invasion was less than sera to CS protein (Table 2). 
However, when primary hepatocytes were used, sera 
M3S3 and M4S3 were significantly more active than 
serum M2S2 against CS protein. When sera from 
rabbits immunized with recombinant vaccinia virus 
v S C ll /1 6  were tested by ISI, only R57S2 had ISI 
activity, whereas R64S2 was inactive. However, the 
rabbit pre-serum R64S0 itself significantly lowered 
the numbers of invaded sporozoites (Table 2), which 
may have obscured R64S2 activity. When rabbit R39 
previously immunized with recombinant yeast P fs l6 - 
S,S particles was boosted with recombinant vaccinia 
virus v S C ll/1 6 , the ISI activity of this antiserum 
(R39v22) increased and was similar to rabbit serum 
R8S2 against CS protein. This correlates with the 
efficient boosting capacity of the recombinant vac­
cinia virus shown by anti-Pfsl6  ELISA activities 
(Table 1). None of the antisera show ed  
transmission-blocking activity.
4. Discussion
A sporozoite vaccine is expected to block either 
sporozoite invasion of hepatocytes or its subsequent 
intrahepatic development. Identification of sporo-
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zoite ligands might permit development of vaccines 
that elicit antibodies that block ligand recognition of 
hepatocyte receptors. It is likely that a series of 
molecular interactions are critical for sporozoite in­
vasion. CS protein Region I and Region II, found in 
both CS protein and TRAP, have been shown to 
specifically bind to hepatoma cells in vitro, and 
antibodies to these regions block sporozoite invasion 
[35-37]. Recently, van Pelt et al. [26] have suggested 
that P . falciparum  sporozoite invasion of human 
hepatocytes involves two distinct 20 and 55-kDa 
membrane proteins, although the sporozoite ligands 
have not been identified. The results reported here 
suggest that the highly conserved P fsl6  protein found 
in both sexual stages and sporozoites [9,10] also 
might be involved in sporozoite invasion.
To obtain more information on the precise biolog­
ical function of the 16-kDa protein and to explore its 
role as a vaccine candidate, immunization studies 
were performed using recombinant P fs l6  vaccinia 
virus, and a P fs l6  fragment fused to the HBsAg, and 
expressed as virus-like particles in the yeast Saccha- 
romyces cerevisiae. In line with previous findings [9] 
all antisera reacted with a 16-kDa protein in Western 
blots prepared from gametocyte or sporozoite ex­
tracts. In the suspension immunofluorescence assay, 
antibodies to the recombinant P fsl6  product reacted 
with the surface of the sporozoite, suggesting that 
these sera recognized the authentic native Pfsl6  anti­
gen. Furthermore, antibodies to the protein con­
structs specifically reduced in vitro invasion of hu­
man hepatoma HepG2-A16 cells and primary human 
hepatocytes. Of interest was our finding that mouse 
anti-Pfs! 6  antibodies were more active in blocking 
invasion of human hepatocytes than anti-CS protein 
antibodies. We have previously demonstrated that 
sera from human volunteers immunized with CS 
protein vaccines and protected to sporozoite chal­
lenge blocked sporozoite invasion of hepatoma 
HepG2-A16 cells but not human hepatocytes [34]. 
Thus, P fs l6  may represent a candidate malaria vac­
cine designed to elicit sporozoite neutralizing anti­
bodies.
Immunoelectron microscopy experiments using 
antisera R57S2 and R64S2 from rabbits infected 
with recombinant vaccinia virus confirm that P fsl6 
is localized on the surface of sporozoites (Fig. 5A) 
and appears to accumulate between hepatoma cell
and the attached sporozoite (Fig. 5B). We also found 
that the Pfsl6  is localized on newly invaded sporo­
zoites as well as P. falciparum  liver stage parasites. 
The liver stages are attractive targets [38-40] for 
vaccine development because they are susceptible 
for immune attack for much longer than sporozoites, 
i.e., at least five days compared to a few minutes 
[40,41]. Moreover, both CD4 + and CD8  4- T cells 
have been shown to attack malaria-infected hepato­
cytes, either by direct cytotoxicity or indirectly by 
cytokines, suggesting that P. falciparum epitopes are 
expressed on the surface of infected hepatocytes in 
association with MHC Class-I or -II molecules 
[40,42-44]. The presence of P fsl6  during P. falci­
parum liver-stage development suggests that P fsl6 
vaccines could also elicit cytotoxic T-cell responses 
directed to P. falciparum-infected hepatocytes.
None of the antisera showed transmission-block- 
ing activity, indicating that P fsl6  probably does not 
play a critical role in the process of transmission of 
the parasite from the human host to the mosquito 
vector. Comparable results were observed in previ­
ous Pfsl6 immunization experiments [9] and this is 
also in agreement with Baker et al. [11] and Bruce et 
al. [12] who demonstrated that P fsl6  is located on 
the parasitophorous vacuole membrane of the game­
tocyte and not on the plasma membrane of gametes. 
Since antigens on the gamete plasma membrane are 
the most likely targets of transmission-blocking anti­
bodies, the absence or low expression of the Pfsl6 
antigen on the gamete plasma membrane may ex­
plain lack of transmission-blocking activity. How­
ever, the location of P fsl6  on the parasitophorous 
vacuole membrane suggests that this antigen may 
play a role during gametocytogenesis or is involved 
in the emergence of macrogametes from the para­
sitophorous vacuole membrane. The possible role of 
Pfsl6  in these processes is currently under investiga­
tion.
In conclusion, the present study confirms that the 
Pfsl6  antigen is expressed on P. falciparum sporo­
zoites. P fsl6  may be involved in sporozoite invasion 
of hepatocytes, since Pfs 16-specific antibodies re­
duced sporozoite invasion into human hepatoma cells 
and human hepatocytes. Since Pfsl6  is also ex­
pressed during P. falciparum  liver-stage develop­
ment, P fsl6  may represent a candidate antigen for 
malaria vaccine development.
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